The global CAR-T Therapy in Haematological Malignancy market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for CAR-T Therapy in Haematological Malignancy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CAR-T Therapy in Haematological Malignancy.

Report Scope

The CAR-T Therapy in Haematological Malignancy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global CAR-T Therapy in Haematological Malignancy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the CAR-T Therapy in Haematological Malignancy companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of CAR-T Therapy in Haematological Malignancy Market Report

Report Metric	Details
Report Name	CAR-T Therapy in Haematological Malignancy Market
CAGR	5%
Segment by Type	Allogeneic Autologous
Segment by Application	Hospitals Cancer Research Centers Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Celgene (Juno Therapeutics), Novartis, Gilead (Kite Pharma), Pfizer, CARsgen Therapeutics, Autolus Therapeutics, Aurora BioPharma, Sorrento Therapeutics, Mustang Bio, Bluebird Bio, Collectis, Allogene Therapeutics, Celyad
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of CAR-T Therapy in Haematological Malignancy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the CAR-T Therapy in Haematological Malignancy Market report?

Ans: The main players in the CAR-T Therapy in Haematological Malignancy Market are Celgene (Juno Therapeutics), Novartis, Gilead (Kite Pharma), Pfizer, CARsgen Therapeutics, Autolus Therapeutics, Aurora BioPharma, Sorrento Therapeutics, Mustang Bio, Bluebird Bio, Collectis, Allogene Therapeutics, Celyad

What are the Application segmentation covered in the CAR-T Therapy in Haematological Malignancy Market report?

Ans: The Applications covered in the CAR-T Therapy in Haematological Malignancy Market report are Hospitals, Cancer Research Centers, Others

What are the Type segmentation covered in the CAR-T Therapy in Haematological Malignancy Market report?

Ans: The Types covered in the CAR-T Therapy in Haematological Malignancy Market report are Allogeneic, Autologous

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global CAR-T Therapy in Haematological Malignancy Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Allogeneic

1.2.3 Autologous

1.3 Market by Application

1.3.1 Global CAR-T Therapy in Haematological Malignancy Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Hospitals

1.3.3 Cancer Research Centers

1.3.4 Others

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global CAR-T Therapy in Haematological Malignancy Market Perspective (2019-2030)

2.2 CAR-T Therapy in Haematological Malignancy Growth Trends by Region

2.2.1 Global CAR-T Therapy in Haematological Malignancy Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 CAR-T Therapy in Haematological Malignancy Historic Market Size by Region (2019-2024)

2.2.3 CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Region (2025-2030)

2.3 CAR-T Therapy in Haematological Malignancy Market Dynamics

2.3.1 CAR-T Therapy in Haematological Malignancy Industry Trends

2.3.2 CAR-T Therapy in Haematological Malignancy Market Drivers

2.3.3 CAR-T Therapy in Haematological Malignancy Market Challenges

2.3.4 CAR-T Therapy in Haematological Malignancy Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top CAR-T Therapy in Haematological Malignancy Players by Revenue

3.1.1 Global Top CAR-T Therapy in Haematological Malignancy Players by Revenue (2019-2024)

3.1.2 Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Players (2019-2024)

3.2 Global CAR-T Therapy in Haematological Malignancy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by CAR-T Therapy in Haematological Malignancy Revenue

3.4 Global CAR-T Therapy in Haematological Malignancy Market Concentration Ratio

3.4.1 Global CAR-T Therapy in Haematological Malignancy Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by CAR-T Therapy in Haematological Malignancy Revenue in 2023

3.5 CAR-T Therapy in Haematological Malignancy Key Players Head office and Area Served

3.6 Key Players CAR-T Therapy in Haematological Malignancy Product Solution and Service

3.7 Date of Enter into CAR-T Therapy in Haematological Malignancy Market

3.8 Mergers & Acquisitions, Expansion Plans

4 CAR-T Therapy in Haematological Malignancy Breakdown Data by Type

4.1 Global CAR-T Therapy in Haematological Malignancy Historic Market Size by Type (2019-2024)

4.2 Global CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Type (2025-2030)

5 CAR-T Therapy in Haematological Malignancy Breakdown Data by Application

5.1 Global CAR-T Therapy in Haematological Malignancy Historic Market Size by Application (2019-2024)

5.2 Global CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America CAR-T Therapy in Haematological Malignancy Market Size (2019-2030)

6.2 North America CAR-T Therapy in Haematological Malignancy Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America CAR-T Therapy in Haematological Malignancy Market Size by Country (2019-2024)

6.4 North America CAR-T Therapy in Haematological Malignancy Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe CAR-T Therapy in Haematological Malignancy Market Size (2019-2030)

7.2 Europe CAR-T Therapy in Haematological Malignancy Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe CAR-T Therapy in Haematological Malignancy Market Size by Country (2019-2024)

7.4 Europe CAR-T Therapy in Haematological Malignancy Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size (2019-2030)

8.2 Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Region (2019-2024)

8.4 Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America CAR-T Therapy in Haematological Malignancy Market Size (2019-2030)

9.2 Latin America CAR-T Therapy in Haematological Malignancy Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America CAR-T Therapy in Haematological Malignancy Market Size by Country (2019-2024)

9.4 Latin America CAR-T Therapy in Haematological Malignancy Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size (2019-2030)

10.2 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Country (2019-2024)

10.4 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Celgene (Juno Therapeutics)

11.1.1 Celgene (Juno Therapeutics) Company Detail

11.1.2 Celgene (Juno Therapeutics) Business Overview

11.1.3 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Introduction

11.1.4 Celgene (Juno Therapeutics) Revenue in CAR-T Therapy in Haematological Malignancy Business (2019-2024)

11.1.5 Celgene (Juno Therapeutics) Recent Development

11.2 Novartis

11.2.1 Novartis Company Detail

11.2.2 Novartis Business Overview

11.2.3 Novartis CAR-T Therapy in Haematological Malignancy Introduction

11.2.4 Novartis Revenue in CAR-T Therapy in Haematological Malignancy Business (2019-2024)

11.2.5 Novartis Recent Development

11.3 Gilead (Kite Pharma)

11.3.1 Gilead (Kite Pharma) Company Detail

11.3.2 Gilead (Kite Pharma) Business Overview

11.3.3 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Introduction

11.3.4 Gilead (Kite Pharma) Revenue in CAR-T Therapy in Haematological Malignancy Business (2019-2024)

11.3.5 Gilead (Kite Pharma) Recent Development

11.4 Pfizer

11.4.1 Pfizer Company Detail

11.4.2 Pfizer Business Overview

11.4.3 Pfizer CAR-T Therapy in Haematological Malignancy Introduction

11.4.4 Pfizer Revenue in CAR-T Therapy in Haematological Malignancy Business (2019-2024)

11.4.5 Pfizer Recent Development

11.5 CARsgen Therapeutics

11.5.1 CARsgen Therapeutics Company Detail

11.5.2 CARsgen Therapeutics Business Overview

11.5.3 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Introduction

11.5.4 CARsgen Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2019-2024)

11.5.5 CARsgen Therapeutics Recent Development

11.6 Autolus Therapeutics

11.6.1 Autolus Therapeutics Company Detail

11.6.2 Autolus Therapeutics Business Overview

11.6.3 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Introduction

11.6.4 Autolus Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2019-2024)

11.6.5 Autolus Therapeutics Recent Development

11.7 Aurora BioPharma

11.7.1 Aurora BioPharma Company Detail

11.7.2 Aurora BioPharma Business Overview

11.7.3 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Introduction

11.7.4 Aurora BioPharma Revenue in CAR-T Therapy in Haematological Malignancy Business (2019-2024)

11.7.5 Aurora BioPharma Recent Development

11.8 Sorrento Therapeutics

11.8.1 Sorrento Therapeutics Company Detail

11.8.2 Sorrento Therapeutics Business Overview

11.8.3 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Introduction

11.8.4 Sorrento Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2019-2024)

11.8.5 Sorrento Therapeutics Recent Development

11.9 Mustang Bio

11.9.1 Mustang Bio Company Detail

11.9.2 Mustang Bio Business Overview

11.9.3 Mustang Bio CAR-T Therapy in Haematological Malignancy Introduction

11.9.4 Mustang Bio Revenue in CAR-T Therapy in Haematological Malignancy Business (2019-2024)

11.9.5 Mustang Bio Recent Development

11.10 Bluebird Bio

11.10.1 Bluebird Bio Company Detail

11.10.2 Bluebird Bio Business Overview

11.10.3 Bluebird Bio CAR-T Therapy in Haematological Malignancy Introduction

11.10.4 Bluebird Bio Revenue in CAR-T Therapy in Haematological Malignancy Business (2019-2024)

11.10.5 Bluebird Bio Recent Development

11.11 Collectis

11.11.1 Collectis Company Detail

11.11.2 Collectis Business Overview

11.11.3 Collectis CAR-T Therapy in Haematological Malignancy Introduction

11.11.4 Collectis Revenue in CAR-T Therapy in Haematological Malignancy Business (2019-2024)

11.11.5 Collectis Recent Development

11.12 Allogene Therapeutics

11.12.1 Allogene Therapeutics Company Detail

11.12.2 Allogene Therapeutics Business Overview

11.12.3 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Introduction

11.12.4 Allogene Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2019-2024)

11.12.5 Allogene Therapeutics Recent Development

11.13 Celyad

11.13.1 Celyad Company Detail

11.13.2 Celyad Business Overview

11.13.3 Celyad CAR-T Therapy in Haematological Malignancy Introduction

11.13.4 Celyad Revenue in CAR-T Therapy in Haematological Malignancy Business (2019-2024)

11.13.5 Celyad Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Celgene (Juno Therapeutics)

Sorrento Therapeutics

Mustang Bio

Bluebird bio

Collectis

Allogene Therapeutics

Celyad

List of Tables

Table 1. Global CAR-T Therapy in Haematological Malignancy Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Allogeneic

Table 3. Key Players of Autologous

Table 4. Global CAR-T Therapy in Haematological Malignancy Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 5. Global CAR-T Therapy in Haematological Malignancy Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 6. Global CAR-T Therapy in Haematological Malignancy Market Size by Region (2019-2024) & (US$ Million)

Table 7. Global CAR-T Therapy in Haematological Malignancy Market Share by Region (2019-2024)

Table 8. Global CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 9. Global CAR-T Therapy in Haematological Malignancy Market Share by Region (2025-2030)

Table 10. CAR-T Therapy in Haematological Malignancy Market Trends

Table 11. CAR-T Therapy in Haematological Malignancy Market Drivers

Table 12. CAR-T Therapy in Haematological Malignancy Market Challenges

Table 13. CAR-T Therapy in Haematological Malignancy Market Restraints

Table 14. Global CAR-T Therapy in Haematological Malignancy Revenue by Players (2019-2024) & (US$ Million)

Table 15. Global CAR-T Therapy in Haematological Malignancy Market Share by Players (2019-2024)

Table 16. Global Top CAR-T Therapy in Haematological Malignancy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CAR-T Therapy in Haematological Malignancy as of 2023)

Table 17. Ranking of Global Top CAR-T Therapy in Haematological Malignancy Companies by Revenue (US$ Million) in 2023

Table 18. Global 5 Largest Players Market Share by CAR-T Therapy in Haematological Malignancy Revenue (CR5 and HHI) & (2019-2024)

Table 19. Key Players Headquarters and Area Served

Table 20. Key Players CAR-T Therapy in Haematological Malignancy Product Solution and Service

Table 21. Date of Enter into CAR-T Therapy in Haematological Malignancy Market

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global CAR-T Therapy in Haematological Malignancy Market Size by Type (2019-2024) & (US$ Million)

Table 24. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Type (2019-2024)

Table 25. Global CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 26. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Type (2025-2030)

Table 27. Global CAR-T Therapy in Haematological Malignancy Market Size by Application (2019-2024) & (US$ Million)

Table 28. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Application (2019-2024)

Table 29. Global CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 30. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Application (2025-2030)

Table 31. North America CAR-T Therapy in Haematological Malignancy Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 32. North America CAR-T Therapy in Haematological Malignancy Market Size by Country (2019-2024) & (US$ Million)

Table 33. North America CAR-T Therapy in Haematological Malignancy Market Size by Country (2025-2030) & (US$ Million)

Table 34. Europe CAR-T Therapy in Haematological Malignancy Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 35. Europe CAR-T Therapy in Haematological Malignancy Market Size by Country (2019-2024) & (US$ Million)

Table 36. Europe CAR-T Therapy in Haematological Malignancy Market Size by Country (2025-2030) & (US$ Million)

Table 37. Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 38. Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Region (2019-2024) & (US$ Million)

Table 39. Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Region (2025-2030) & (US$ Million)

Table 40. Latin America CAR-T Therapy in Haematological Malignancy Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 41. Latin America CAR-T Therapy in Haematological Malignancy Market Size by Country (2019-2024) & (US$ Million)

Table 42. Latin America CAR-T Therapy in Haematological Malignancy Market Size by Country (2025-2030) & (US$ Million)

Table 43. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 44. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Country (2019-2024) & (US$ Million)

Table 45. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Country (2025-2030) & (US$ Million)

Table 46. Celgene (Juno Therapeutics) Company Detail

Table 47. Celgene (Juno Therapeutics) Business Overview

Table 48. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Product

Table 49. Celgene (Juno Therapeutics) Revenue in CAR-T Therapy in Haematological Malignancy Business (2019-2024) & (US$ Million)

Table 50. Celgene (Juno Therapeutics) Recent Development

Table 51. Novartis Company Detail

Table 52. Novartis Business Overview

Table 53. Novartis CAR-T Therapy in Haematological Malignancy Product

Table 54. Novartis Revenue in CAR-T Therapy in Haematological Malignancy Business (2019-2024) & (US$ Million)

Table 55. Novartis Recent Development

Table 56. Gilead (Kite Pharma) Company Detail

Table 57. Gilead (Kite Pharma) Business Overview

Table 58. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Product

Table 59. Gilead (Kite Pharma) Revenue in CAR-T Therapy in Haematological Malignancy Business (2019-2024) & (US$ Million)

Table 60. Gilead (Kite Pharma) Recent Development

Table 61. Pfizer Company Detail

Table 62. Pfizer Business Overview

Table 63. Pfizer CAR-T Therapy in Haematological Malignancy Product

Table 64. Pfizer Revenue in CAR-T Therapy in Haematological Malignancy Business (2019-2024) & (US$ Million)

Table 65. Pfizer Recent Development

Table 66. CARsgen Therapeutics Company Detail

Table 67. CARsgen Therapeutics Business Overview

Table 68. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Product

Table 69. CARsgen Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2019-2024) & (US$ Million)

Table 70. CARsgen Therapeutics Recent Development

Table 71. Autolus Therapeutics Company Detail

Table 72. Autolus Therapeutics Business Overview

Table 73. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Product

Table 74. Autolus Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2019-2024) & (US$ Million)

Table 75. Autolus Therapeutics Recent Development

Table 76. Aurora BioPharma Company Detail

Table 77. Aurora BioPharma Business Overview

Table 78. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Product

Table 79. Aurora BioPharma Revenue in CAR-T Therapy in Haematological Malignancy Business (2019-2024) & (US$ Million)

Table 80. Aurora BioPharma Recent Development

Table 81. Sorrento Therapeutics Company Detail

Table 82. Sorrento Therapeutics Business Overview

Table 83. Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Product

Table 84. Sorrento Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2019-2024) & (US$ Million)

Table 85. Sorrento Therapeutics Recent Development

Table 86. Mustang Bio Company Detail

Table 87. Mustang Bio Business Overview

Table 88. Mustang Bio CAR-T Therapy in Haematological Malignancy Product

Table 89. Mustang Bio Revenue in CAR-T Therapy in Haematological Malignancy Business (2019-2024) & (US$ Million)

Table 90. Mustang Bio Recent Development

Table 91. Bluebird Bio Company Detail

Table 92. Bluebird Bio Business Overview

Table 93. Bluebird Bio CAR-T Therapy in Haematological Malignancy Product

Table 94. Bluebird Bio Revenue in CAR-T Therapy in Haematological Malignancy Business (2019-2024) & (US$ Million)

Table 95. Bluebird Bio Recent Development

Table 96. Collectis Company Detail

Table 97. Collectis Business Overview

Table 98. Collectis CAR-T Therapy in Haematological Malignancy Product

Table 99. Collectis Revenue in CAR-T Therapy in Haematological Malignancy Business (2019-2024) & (US$ Million)

Table 100. Collectis Recent Development

Table 101. Allogene Therapeutics Company Detail

Table 102. Allogene Therapeutics Business Overview

Table 103. Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Product

Table 104. Allogene Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2019-2024) & (US$ Million)

Table 105. Allogene Therapeutics Recent Development

Table 106. Celyad Company Detail

Table 107. Celyad Business Overview

Table 108. Celyad CAR-T Therapy in Haematological Malignancy Product

Table 109. Celyad Revenue in CAR-T Therapy in Haematological Malignancy Business (2019-2024) & (US$ Million)

Table 110. Celyad Recent Development

Table 111. Research Programs/Design for This Report

Table 112. Key Data Information from Secondary Sources

Table 113. Key Data Information from Primary Sources

List of Figures

Figure 1. Global CAR-T Therapy in Haematological Malignancy Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global CAR-T Therapy in Haematological Malignancy Market Share by Type: 2023 VS 2030

Figure 3. Allogeneic Features

Figure 4. Autologous Features

Figure 5. Global CAR-T Therapy in Haematological Malignancy Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 6. Global CAR-T Therapy in Haematological Malignancy Market Share by Application: 2023 VS 2030

Figure 7. Hospitals Case Studies

Figure 8. Cancer Research Centers Case Studies

Figure 9. Others Case Studies

Figure 10. CAR-T Therapy in Haematological Malignancy Report Years Considered

Figure 11. Global CAR-T Therapy in Haematological Malignancy Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 12. Global CAR-T Therapy in Haematological Malignancy Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 13. Global CAR-T Therapy in Haematological Malignancy Market Share by Region: 2023 VS 2030

Figure 14. Global CAR-T Therapy in Haematological Malignancy Market Share by Players in 2023

Figure 15. Global Top CAR-T Therapy in Haematological Malignancy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CAR-T Therapy in Haematological Malignancy as of 2023)

Figure 16. The Top 10 and 5 Players Market Share by CAR-T Therapy in Haematological Malignancy Revenue in 2023

Figure 17. North America CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 18. North America CAR-T Therapy in Haematological Malignancy Market Share by Country (2019-2030)

Figure 19. United States CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 20. Canada CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 21. Europe CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. Europe CAR-T Therapy in Haematological Malignancy Market Share by Country (2019-2030)

Figure 23. Germany CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. France CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. U.K. CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. Italy CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Russia CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Nordic Countries CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Share by Region (2019-2030)

Figure 31. China CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Japan CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. South Korea CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. India CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Australia CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Latin America CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Latin America CAR-T Therapy in Haematological Malignancy Market Share by Country (2019-2030)

Figure 39. Mexico CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Brazil CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Share by Country (2019-2030)

Figure 43. Turkey CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Saudi Arabia CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Celgene (Juno Therapeutics) Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2019-2024)

Figure 46. Novartis Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2019-2024)

Figure 47. Gilead (Kite Pharma) Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2019-2024)

Figure 48. Pfizer Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2019-2024)

Figure 49. CARsgen Therapeutics Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2019-2024)

Figure 50. Autolus Therapeutics Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2019-2024)

Figure 51. Aurora BioPharma Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2019-2024)

Figure 52. Sorrento Therapeutics Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2019-2024)

Figure 53. Mustang Bio Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2019-2024)

Figure 54. Bluebird Bio Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2019-2024)

Figure 55. Collectis Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2019-2024)

Figure 56. Allogene Therapeutics Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2019-2024)

Figure 57. Celyad Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2019-2024)

Figure 58. Bottom-up and Top-down Approaches for This Report

Figure 59. Data Triangulation

Figure 60. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-6T7647

Tue Oct 08 00:00:00 UTC 2024

Add to Cart

Anti-Oral Mucositis Drug - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-5V5924

Mon Oct 07 00:00:00 UTC 2024

Add to Cart

Transarterial Chemoembolization (TACE) - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-18Y13983

Mon Oct 07 00:00:00 UTC 2024

Add to Cart

Multiple Myeloma Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-37R6886

Mon Oct 07 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global CAR-T Therapy in Haematological Malignancy Market Research Report 2024

Published Date: June 2024

Report Code: QYRE-Auto-0K13823

Global CAR-T Therapy in Haematological Malignancy Market Research Report 2024

FEATURED COMPANIES

CAR-T Therapy in Haematological Malignancy Market Size

CAR-T Therapy in Haematological Malignancy Market

Report Scope

Scope of CAR-T Therapy in Haematological Malignancy Market Report

Chapter Outline

FAQ for this report

Who are the main players in the CAR-T Therapy in Haematological Malignancy Market report?

What are the Application segmentation covered in the CAR-T Therapy in Haematological Malignancy Market report?

What are the Type segmentation covered in the CAR-T Therapy in Haematological Malignancy Market report?

FEATURED COMPANIES

RELATED REPORTS